Quoin Pharmaceuticals' NETHERTON NOW Campaign Garners 24M Impressions, Spotlights Rare Disease Awareness

Event summary

  • Quoin Pharmaceuticals' NETHERTON NOW awareness campaign generated 24M impressions and 2M video views during Rare Disease Month 2025.
  • The campaign focuses on Netherton Syndrome, a rare genetic skin disorder with no approved treatment, affecting 10–20% of newborns fatally.
  • Quoin's lead investigational candidate, QRX003, is in late-stage pivotal clinical trials for Netherton Syndrome.
  • The company's pipeline includes four products targeting multiple rare and orphan indications.

The big picture

Quoin Pharmaceuticals' focus on rare diseases like Netherton Syndrome aligns with the growing industry trend of targeting orphan indications, where high unmet medical needs can justify premium pricing and faster regulatory pathways. The company's strategic emphasis on patient advocacy through campaigns like NETHERTON NOW not only raises awareness but also builds a foundation for future commercial success by fostering a engaged patient community. The success of QRX003 in clinical trials could position Quoin as a key player in the rare disease space, potentially attracting partnerships or acquisitions.

What we're watching

Clinical Progress
The pace at which QRX003 advances through late-stage trials will determine Quoin's ability to address the significant unmet medical needs of Netherton Syndrome patients.
Regulatory Pathways
Whether Quoin can successfully navigate regulatory approvals for QRX003 will be critical for commercializing the treatment.
Awareness Impact
How the continued growth of the NETHERTON NOW campaign translates into broader medical and advocacy community engagement and potential patient recruitment for clinical trials.